Acorus Therapeutics

Acorus Therapeutics is a Cambridge-based biotechnology company dedicated to the discovery and development of novel treatments for metabolic disorders, with a specific focus on obesity and type 2 diabetes. Established in 2023, the company leverages the deep scientific expertise of its founders in the fields of endocrine physiology and metabolic regulation. Acorus aims to develop next-generation multi-agonist therapies that target key metabolic pathways, including the GLP-1, GIP, and glucagon receptors, to provide superior weight loss and glycemic control. The company is currently in the pre-clinical stage, advancing a pipeline of candidates designed to offer improved delivery and tolerability compared to existing injectable therapies. By integrating cutting-edge research with drug development experience, Acorus Therapeutics seeks to address the global epidemic of cardiometabolic disease.